Skip to main content

WELTRUZA™ receives FDA Approval  •  View webcast replay

Hit enter to search or ESC to close
Close Search
MedincellMedincellMedincell
search
Menu
  • About Us
    • Impact companyPurposeful innovation coupled with a responsible company model can positively impact Global Health
    • Our peopleOur strength: valuing and nurturing our team’s entrepreneurial spirit, expertise, and dedication
    • Leadership TeamSeasoned leaders unite to tackle global health challenges
  • Science
    • UZEDY®Relapse prevention long-acting treatment for schizophrenia
    • WELTRUZA™Once-monthly long-acting olanzapine for adults with Schizophrenia.
    • R&D PipelineAdvancing therapeutic care with precision Delivery
    • BEPO® TechnologyOur technology platform to develop long-acting treatments
    • PublicationsFacilitate collaboration with our collection of scientific articles and presentations
  • Responsibility
    • Our commitmentsTransforming global health with purposeful innovation
    • Code and policiesHigh standards for all company’s stakeholders
    • 2026 ESG reportSocial and environmental information about the company and its activities
  • Careers
    • Our vision & our valuesSee how our HR vision and values shape a dynamic workforce
    • Work environment & benefitsExplore the benefits and environment driving our team’s success
    • Join usEmbark on a career journey where your talents meet opportunity
  • News & events
    • NewsroomLatest updates and announcements, the gateway to all press releases
    • EventsEarnings calls, conferences, General Meeting: live and replay
  • Investors
    • OverviewAll information and news about Medincell stock
    • Reports & regulated informationFinancial reports, operational updates, and shareholder information
    • General MeetingAll documents related to the Medincell Shareholders’ Meetings
    • Leadership teamSeasoned leaders unite to tackle global health challenges
  • Contact
  • EN
  • FR
  • search
Category

Home

Medincell Reports FY 2025-26 Annual Results

June 16, 2026
June 16, 2026

Videoconference and publication of annual financial results, Tuesday, June 16, 2026

May 28, 2026

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

May 26, 2026

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults

May 21, 2026

UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year

April 29, 2026

Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation

April 22, 2026

Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation

April 21, 2026

EIB Waives its Right to Cash Settlement on Medincell Warrants

March 26, 2026

Medincell announces successful c. €48 million Private Placement

March 6, 2026

Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026

March 4, 2026
  • Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 21
  • Next

Articles récents

  • Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)
  • Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
  • Investor Webcast – WELTRUZA™ FDA Approval
  • General Meeting 2026 (French)
  • Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm

Commentaires récents

No comments to show.

About us

Impact company
Our people
Leadership Team

Science

UZEDY®
WELTRUZA™
R&D Pipeline
BEPO® Technology
Publications

Careers

Our vision & our values
Work environment & benefits
Join us

Responsability

Our commitments
Code and policies
2026 ESG report

News & events

Newsroom
Events

Investors

Overview
Reports & regulated information
General Meeting
Leadership team

Ressources & contact

Contact
Ethics line
Legal notices
Privacy policy

© 2026 Medincell. All rights reserved.

Website by ScreenUp

Close Menu
  • Home
  • About Us
    • Impact company
    • Our people
    • Leadership team
  • Science
    • UZEDY®
    • WELTRUZA™
    • R&D Pipeline
    • BEPO® Technology
    • Publications
  • Responsibility
    • Our commitments
    • Code and policies
    • 2025 ESG Report
  • Careers
    • Our vision & our values
    • Work environment & benefits
    • Join us
  • News & events
    • News
    • Events
  • Investors
    • Overview
    • Regulated information
    • General Meeting
    • Leadership team
  • Contact
  • FR